This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

CSPC Wins China Trial Nod for First mRNA-LNP Dual-Target CAR-T Therapy

Tipranks - Tipranks - Wed Jun 3, 6:04AM CDT

Claim 55% Off TipRanks

CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.

CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYS6063 Injection, described as the world’s first mRNA-LNP-based dual-target CAR-T cell therapy. The product is designed to express CARs targeting both CD19 and BCMA, enabling precise elimination of CD19- and BCMA-positive cells and showing strong preclinical safety and efficacy.

The initial clinical indication is relapsed or refractory systemic lupus erythematosus, with potential to extend into other B-cell and plasma cell–mediated autoimmune diseases such as myasthenia gravis, rheumatoid arthritis and ANCA-associated vasculitis, as well as blood cancers including multiple myeloma and B-cell lymphoma. This regulatory milestone strengthens CSPC’s strategic position in the cell therapy field and lays groundwork for further development of in vivo-generated CAR-T and other next-generation cell therapy products, potentially enhancing its competitiveness in cutting-edge immunotherapies.

The most recent analyst rating on (HK:1093) stock is a Buy
with a HK$13.05 price target.
To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,
see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on developing innovative therapies, including advanced biologics and cell therapies. The group targets major disease areas such as autoimmune disorders and hematological malignancies, aiming to expand its presence in high-value segments of China’s healthcare market.

Average Trading Volume: 93,880,749

Technical Sentiment Signal: Buy

Current Market Cap: HK$86.27B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).